Podocyte as a potential target of inflammation: Role of pioglitazone hydrochloride in patients with type 2 diabetes

Endocrine Practice

Volumn 18, Issue 4, 2012, Pages 493-498

  Xing, Yan ^a   Ye, Shandong ^a   Hu, Yuanyuan ^a   Chen, Yan ^b  

^a ANHUI MEDICAL UNIVERSITY   (China)

^b ANHUI PROVINCIAL HOSPITAL   (China)

Author keywords

[No Author keywords available]

Indexed keywords

ACARBOSE; ALBUMIN; CREATININE; GLICLAZIDE; GLIMEPIRIDE; GLUCOSE; HEMOGLOBIN A1C; METFORMIN; MONOCYTE CHEMOTACTIC PROTEIN 1; PIOGLITAZONE; PODOCALYXIN;

ADULT; AGED; ANTIINFLAMMATORY ACTIVITY; ARTICLE; CONTROLLED STUDY; CREATININE URINE LEVEL; DIASTOLIC BLOOD PRESSURE; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; FEMALE; GLUCOSE BLOOD LEVEL; HUMAN; INFLAMMATION; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; NON INSULIN DEPENDENT DIABETES MELLITUS; PODOCYTE; PROTEIN URINE LEVEL; RANDOMIZED CONTROLLED TRIAL; RENAL PROTECTION; SYSTOLIC BLOOD PRESSURE; URINARY EXCRETION; URINE SEDIMENT;

ACARBOSE; ADULT; AGED; ANTI-INFLAMMATORY AGENTS; BIOLOGICAL MARKERS; CHEMOKINE CCL2; DIABETES MELLITUS, TYPE 2; DIABETIC NEPHROPATHIES; DOUBLE-BLIND METHOD; DRUG THERAPY, COMBINATION; FEMALE; HUMANS; HYPERGLYCEMIA; HYPOGLYCEMIC AGENTS; MALE; METFORMIN; MIDDLE AGED; PODOCYTES; PROTECTIVE AGENTS; SIALOGLYCOPROTEINS; SOLUBILITY; THIAZOLIDINEDIONES;

EID: 84864710918     PISSN: 1530891X     EISSN: 19342403     Source Type: Journal    
DOI: 10.4158/EP11378.OR     Document Type: Article

References (28)

1. Manabe I. Chronic infammation links cardiovascular, metabolic and renal diseases. Circ J. 2011;75:2739-2748.
2. Stieger N, Worthmann K, Schiffer M. The role of meta-bolic and haemodynamic factors in podocyte injury in dia-betes. Diabetes Metab Res Rev. 2011;27:207-215.
3. Wada T, Furuichi K, Sakai N, et al. Up-regulation of monocyte chemoattractant protein-1 in tubulointerstitial lesions of human diabetic nephropathy Kidney Int. 2000; 58:1492-1499.
4. Murakoshi M, Tanimoto M, Gohda T, et al. Mindin: a novel marker for podocyte injury in diabetic nephropathy Nephrol Dial Transplant. 2011;26:2153-2160.
5. Sato Y, Wharram BL, Lee SK, et al. Urine podocyte mRNAs mark progression of renal disease. J Am Soc Nephrol. 2009;20:1041-1052.
6. Skoberne A, Konieczny A, Schiffer M. Glomerular epi-thelial cells in the urine: what has to be done to make them worthwhile? Am J Physiol Renal Physiol. 2009;296: F230-F241.
7. Papanas N, Katsiki N, Hatzitolios AI, Maltezos E. Pioglitazone: a valuable component of combination therapy for type 2 diabetes mellitus. Expert Opin Pharmacother. 2011;12:1457-1461.
8. Okada T, Wada J, Hida K, et al. Thiazolidinediones ameliorate diabetic nephropathy via cell cycle-dependent mechanisms. Diabetes. 2006;55:1666-1677.
9. Kanjanabuch T, Ma LJ, Chen J, et al. PPAR-gamma ago-nist protects podocytes from injury. Kidney Int. 2007;71: 1232-1239.
10. Kanno K, Kawachi H, Uchida Y, Hara M, Shimizu F, Uchiyama M. Urinary sediment podocalyxin in children with glomerular diseases. Nephron Clin Pract. 2003;95: c91-c99
11. Toblli JE, Ferrini MG, Cao G, Vernet D, Angerosa M, Gonzalez-Cadavid NF. Antifbrotic effects of pioglitazone on the kidney in a rat model of type 2 diabetes mellitus. Nephrol Dial Transplant. 2009;24:2384-2391.
12. Hu YY, Ye SD, Zhao LL, Zheng M, Chen Y. Hydrochloride pioglitazone decreases urinary TGF-beta1 excretion in type 2 diabetics. Eur J Clin Invest. 2010;40:571-574.
13. Nakamura T, Ushiyama C, Osada S, Hara M, Shimada N, Koide H. Pioglitazone reduces urinary podocyte excre-tion in type 2 diabetes patients with microalbuminuria. Metabolism. 2001;50:1193-1196.
14. Hartner A, Veelken R, Wittmann M, Cordasic N, Hilgers KF. Effects of diabetes and hypertension on macrophage infltration and matrix expansion in the rat kidney. BMC Nephrol. 2005;6:6.
15. Tesch GH. MCP-1/CCL2: a new diagnostic marker and therapeutic target for progressive renal injury in diabetic nephropathy Am J Physiol Renal Physiol. 2008;294: F697-F701.
16. Han SY, So GA, Jee YH, et al. Effect of retinoic acid in experimental diabetic nephropathy Immunol Cell Biol. 2004;82:568-576.
17. Tarabra E, Giunti S, Barutta F, et al. Effect of the mono-cyte chemoattractant protein-1/CC chemokine receptor 2 system on nephrin expression in streptozotocin-treated mice and human cultured podocytes. Diabetes. 2009;58: 2109-2118.
18. Ye S, Zheng M, Hu Y, Wu F, Zhao L, Chen Y. Hydrochloride pioglitazone decreases urinary monocyte chemoattractant protein-1 excretion in type 2 diabetics. Diabetes Res Clin Pract. 2010;88:247-251.
19. Lee EY, Chung CH, Khoury CC, et al. The monocyte chemoattractant protein-1/CCR2 loop, inducible by TGF-beta, increases podocyte motility and albumin permeabil-ity. Am J Physiol Renal Physiol. 2009;297:F85-F94.
20. Navarro-González JF, Mora-Fernández C, Muros de Fuentes M, García-Pérez J. Infammatory molecules and pathways in the pathogenesis of diabetic nephropathy Nat Rev Nephrol. 2011;7:327-340.
21. Sayyed SG, Ryu M, Kulkarni OP, et al. An orally active chemokine receptor CCR2 antagonist prevents glomerulo-sclerosis and renal failure in type 2 diabetes. Kidney Int. 2011;80:68-78.
22. Sarafdis PA, Stafylas PC, Georgianos PI, Saratzis AN, Lasaridis AN. Effect of thiazolidinediones on albuminuria and proteinuria in diabetes: a meta-analysis. Am J Kidney Dis. 2010;55:835-847.
23. Hirasawa Y, Matsui Y, Yamane K, et al. Pioglitazone improves obesity type diabetic nephropathy: relation to the mitigation of renal oxidative reaction. Exp Anim. 2008;57: 423-432.
24. Bao Y, Jia RH, Yuan J, Li J. Rosiglitazone ameliorates diabetic nephropathy by inhibiting reactive oxygen species and its downstream-signaling pathways. Pharmacology. 2007;80:57-64.
25. Yuan X, Liu N. Pioglitazone suppresses advanced glyca-tion end product-induced expression of plasminogen acti-vator inhibitor-1 in vascular smooth muscle cells. J Genet Genomics. 2011;38:193-200.
26. Jauregui A, Mintz DH, Mundel P, Fornoni A. Role of altered insulin signaling pathways in the pathogenesis of podocyte malfunction and microalbuminuria. Curr Opin Nephrol Hypertens. 2009;18:539-545.
27. Zheng M, Ye S, Zhai Z, et al. Rosiglitazone protects dia-betic rats against kidney disease through the suppression of renal monocyte chemoattractant protein-1 expression. J Diabetes Complications. 2009;23:124-129.
28. Setti G, Hayward A, Dessapt C, et al. Peroxisome pro-liferator-activated receptor-gamma-agonist rosiglitazone prevents albuminuria but not glomerulosclerosis in experi-mental diabetes. Am J Nephrol. 2010;32:393-402.